A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

J1B-MC-FRCC -

The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis (eczema). The study has three parts. Each participant will enroll in one part. The study will last 12 to 24 weeks, depending on part.

Trial Summary

Age Range
18 - 65 years
Conditions the trial is for
Atopic Dermatitis
What the trial is testing?
LY3454738
Could I receive a Placebo?
Yes
Enrollment Goal
128
Trial Dates
Nov 29, 2018 - Sep 7, 2021
How long will I be in the trial?
The study will last up to 24 week and may include up to 12 visits.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must weigh at least 110 pounds (50 kilograms) - Japanese participants must have all biological parents and grandparents born in Japan and be of exclusive Japanese descent

  • Participants with atopic dermatitis (AD) must have a diagnosis of AD for at least 12 months. The disease symptoms must be severe enough that they do not respond well to medicines that are applied to the skin

  • Participants with AD must agree to use moisturizer daily

Participants Must Not:

  • Participants must not have received certain biologic medications in a specific time frame. This will be discussed with the study doctor

  • Participants with AD must not have received steroids (except those applied to the skin) in the past 6 weeks prior to randomization

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.